论文部分内容阅读
目的:探讨低分子肝素钙联合血塞通治疗急性脑梗死的临床疗效。方法:以近年来于我院治疗的104例急性脑梗死患者为研究对象,将患者随机分为常规组和观察组各52例,常规组在治疗中使用血塞通并配合常规方法进行治疗,观察组在常规组基础上增加使用低分子肝素钙。结果:治疗后观察组患者有效率达92.3%,神经功能缺损评分为6.5±4.7分,明显优于常规组75.0%和12.4±6.8分,并具有统计学差异(均P<0.05)。结论:采取低分子肝素钙联合血塞通对急性脑梗死患者进行治疗安全可靠,对于急性脑梗死的临床治疗具有参考价值。
Objective: To investigate the clinical efficacy of low molecular weight heparin combined with Xuesaitong in the treatment of acute cerebral infarction. Methods: A total of 104 patients with acute cerebral infarction treated in our hospital in recent years were selected as study subjects. The patients were randomly divided into routine and observation groups of 52 cases. Conventional group was treated with Xuesaitong with conventional method. The observation group increased the use of low molecular weight heparin calcium on the basis of the conventional group. Results: After treatment, the effective rate of the observation group was 92.3% and the neurological deficit score was 6.5 ± 4.7, which was significantly better than that of the conventional group (75.0% vs 12.4 ± 6.8) (all P <0.05). Conclusion: Low molecular weight heparin combined with Xuesaitong can be safely and reliably used in patients with acute cerebral infarction, which is of reference value for the clinical treatment of acute cerebral infarction.